Alyeska Investment Group L.P. boosted its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 52.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,808,514 shares of the company's stock after acquiring an additional 3,041,058 shares during the period. Alyeska Investment Group L.P. owned 3.89% of Gossamer Bio worth $7,968,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after purchasing an additional 13,902 shares during the last quarter. Silverarc Capital Management LLC boosted its stake in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after acquiring an additional 526,495 shares during the last quarter. Allostery Investments LP bought a new position in Gossamer Bio in the fourth quarter valued at approximately $555,000. Geode Capital Management LLC grew its holdings in Gossamer Bio by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after acquiring an additional 38,084 shares during the period. Finally, Opti Capital Management LP bought a new stake in shares of Gossamer Bio during the 4th quarter valued at $165,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.
Gossamer Bio Stock Up 5.9 %
NASDAQ:GOSS opened at $1.25 on Tuesday. The stock has a market cap of $284.03 million, a price-to-earnings ratio of -3.91 and a beta of 1.82. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $0.98. Gossamer Bio, Inc. has a 1 year low of $0.50 and a 1 year high of $1.55.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.15). The business had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. As a group, equities analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently commented on GOSS. The Goldman Sachs Group decreased their price objective on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. Finally, Wedbush reissued an "outperform" rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th.
Get Our Latest Research Report on Gossamer Bio
Gossamer Bio Company Profile
(
Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
See Also
Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
